LemCourse
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Alemtuzumab
CAMPATH-1 antigen inhibitor
What it measured
Main measures
- Change in neurological examination (Confirmed relapse[s])
Relapses
Other measures (1)
1. Percentage of relapse-free participants
Relapses
Who could take part
Relapsing MS
Inclusion: -A patient with RRMS who has received two courses of alemtuzumab and has an active disease defined by clinical or imaging features. Exclusion: -Patients who have any of the contraindications noted in the Summary of Product Characteristics (SmPC) of alemtuzumab.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Evaluation of effectiveness of an additional alemtuzumab course in patients with relapsing remitting multiple sclerosis (RRMS) with disease activity after 2 courses.
Loading reviews and guidelines…
Related trials
- HiHat
Phase 2 · Recruiting
Still running
- MS700568_0198
Phase 4 · Not yet recruiting
Still running
- Cladribine Tablets Level of Response Predictors in Clinic…
Running, not recruiting
Still running
- ADAs to Alemtuzumab
Completed
No result found
- A Study to Learn More About The Safety of Diroximel Fumar…
Running, not recruiting
Still running
- COAST
Phase 2 · Stopped early
Stopped early
History
Started
Apr 2016
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error